Light therapy for multiple sclerosis-associated fatigue: a randomized, controlled phase II trial
Background Bright white light therapy (LT) can improve fatigue in several disease states but has not been studied in multiple sclerosis (MS). Objective To determine whether controlled home-based LT is feasible, tolerable, and well-adhered to in MS-associated fatigue. Methods A randomized, controlled...
Gespeichert in:
| Veröffentlicht in: | Journal of neurology 2020-08, Vol.267 (8), p.2319-2327 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 2327 |
|---|---|
| container_issue | 8 |
| container_start_page | 2319 |
| container_title | Journal of neurology |
| container_volume | 267 |
| creator | Mateen, Farrah J. Vogel, Andre C. Kaplan, Tamara B. Hotan, Gladia C. Grundy, Sara J. Holroyd, Kathryn B. Manalo, Natalie Stauder, Matthew Videnovic, Aleksandar |
| description | Background
Bright white light therapy (LT) can improve fatigue in several disease states but has not been studied in multiple sclerosis (MS).
Objective
To determine whether controlled home-based LT is feasible, tolerable, and well-adhered to in MS-associated fatigue.
Methods
A randomized, controlled trial of twice-daily 1-h bright white LT (BWLT) (10,000 lx, active arm) versus dim red LT (DRLT) ( |
| doi_str_mv | 10.1007/s00415-020-09845-w |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2394879737</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2423338947</sourcerecordid><originalsourceid>FETCH-LOGICAL-c419t-26ea7a62bcc5c4c01a7de2e8e63247324fb9a359987510ef240295c44b0899c23</originalsourceid><addsrcrecordid>eNp9kD1vFDEQhi1ERI7AH6BAlmgocBh_7O2aLor4OOkkGqiNzzt758i7XmyvovDr4-MCSBQpRlPMM--MHkJecbjkAO37DKB4w0AAA92pht0-ISuupGBcNfopWYFUwBrZqHPyPOcbAKiUfkbOpZBS8nW3Ij-2fn8otBww2fmODjHRcQnFzwFpdgFTzD4zm3N03hbs6WCL3y_4gVqa7NTH0f_C_h11cSophlCJ-WAz0s2GluRteEHOBhsyvnzoF-T7p4_frr-w7dfPm-urLXOK68LEGm1r12LnXOOUA27bHgV2uJZCtbWGnbay0bprGw44CAVCV1LtoNPaCXlB3p5y5xR_LpiLGX12GIKdMC7ZCKlV1-pWthV98x96E5c01e-MUEcznVZHSpwoVx3khIOZkx9tujMczNG_Ofk31b_57d_c1qXXD9HLbsT-78of4RWQJyDX0bTH9O_2I7H32MaQdQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2423338947</pqid></control><display><type>article</type><title>Light therapy for multiple sclerosis-associated fatigue: a randomized, controlled phase II trial</title><source>SpringerLink Journals - AutoHoldings</source><creator>Mateen, Farrah J. ; Vogel, Andre C. ; Kaplan, Tamara B. ; Hotan, Gladia C. ; Grundy, Sara J. ; Holroyd, Kathryn B. ; Manalo, Natalie ; Stauder, Matthew ; Videnovic, Aleksandar</creator><creatorcontrib>Mateen, Farrah J. ; Vogel, Andre C. ; Kaplan, Tamara B. ; Hotan, Gladia C. ; Grundy, Sara J. ; Holroyd, Kathryn B. ; Manalo, Natalie ; Stauder, Matthew ; Videnovic, Aleksandar</creatorcontrib><description>Background
Bright white light therapy (LT) can improve fatigue in several disease states but has not been studied in multiple sclerosis (MS).
Objective
To determine whether controlled home-based LT is feasible, tolerable, and well-adhered to in MS-associated fatigue.
Methods
A randomized, controlled trial of twice-daily 1-h bright white LT (BWLT) (10,000 lx, active arm) versus dim red LT (DRLT) (< 300 lx, control arm) was performed. Adults with MS-associated fatigue were enrolled for 10 weeks: 2-week baseline, 4-week intervention, 4-week washout.
Results
41 participants were enrolled; 35 were randomized (average age 42 years, 80% female; BWLT
n
= 20; DRLT
n
= 15). 31 were in the intention to treat analysis. The average duration of LT sessions was similar between groups (BWLT 60.9 min, DRLT 61.5 min,
p
= 0.70). The most commonly reported adverse event was headache. There were no events that led to discontinuation. Baseline fatigue was severe in both arms (each 53/63 points on the Fatigue Severity Scale (FSS),
p
= 0.92). FSS was lower following BWLT (FSS 45.8 post-LT,
p
= 0.04; 44.9 post-washout,
p
= 0.02 intra-group compared to baseline FSS) and DRLT (FSS 46.7 post-LT,
p
= 0.03; 43.9 post-washout,
p
= 0.002 intragroup compared to baseline FSS). There was no difference between BWLT and DRLT groups in the magnitude of reduction of FSS scores (
p
= 0.81 after LT;
p
= 0.77 after washout for between group comparisons). Similarly, MS quality of life metrics improved in both arms but were not significantly different between groups after LT (
p
= 0.22) or washout.
Conclusions
LT is safe, feasible, and well-tolerated in people with MS-associated fatigue. Improvement in both light spectra likely indicates a strong placebo effect for the DRLT group.</description><identifier>ISSN: 0340-5354</identifier><identifier>EISSN: 1432-1459</identifier><identifier>DOI: 10.1007/s00415-020-09845-w</identifier><identifier>PMID: 32333168</identifier><language>eng</language><publisher>Berlin/Heidelberg: Springer Berlin Heidelberg</publisher><subject>Fatigue ; Headache ; Light therapy ; Medicine ; Medicine & Public Health ; Multiple sclerosis ; Neurology ; Neuroradiology ; Neurosciences ; Original Communication ; Placebos ; Quality of life</subject><ispartof>Journal of neurology, 2020-08, Vol.267 (8), p.2319-2327</ispartof><rights>Springer-Verlag GmbH Germany, part of Springer Nature 2020</rights><rights>Springer-Verlag GmbH Germany, part of Springer Nature 2020.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c419t-26ea7a62bcc5c4c01a7de2e8e63247324fb9a359987510ef240295c44b0899c23</citedby><cites>FETCH-LOGICAL-c419t-26ea7a62bcc5c4c01a7de2e8e63247324fb9a359987510ef240295c44b0899c23</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s00415-020-09845-w$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s00415-020-09845-w$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,780,784,27923,27924,41487,42556,51318</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32333168$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Mateen, Farrah J.</creatorcontrib><creatorcontrib>Vogel, Andre C.</creatorcontrib><creatorcontrib>Kaplan, Tamara B.</creatorcontrib><creatorcontrib>Hotan, Gladia C.</creatorcontrib><creatorcontrib>Grundy, Sara J.</creatorcontrib><creatorcontrib>Holroyd, Kathryn B.</creatorcontrib><creatorcontrib>Manalo, Natalie</creatorcontrib><creatorcontrib>Stauder, Matthew</creatorcontrib><creatorcontrib>Videnovic, Aleksandar</creatorcontrib><title>Light therapy for multiple sclerosis-associated fatigue: a randomized, controlled phase II trial</title><title>Journal of neurology</title><addtitle>J Neurol</addtitle><addtitle>J Neurol</addtitle><description>Background
Bright white light therapy (LT) can improve fatigue in several disease states but has not been studied in multiple sclerosis (MS).
Objective
To determine whether controlled home-based LT is feasible, tolerable, and well-adhered to in MS-associated fatigue.
Methods
A randomized, controlled trial of twice-daily 1-h bright white LT (BWLT) (10,000 lx, active arm) versus dim red LT (DRLT) (< 300 lx, control arm) was performed. Adults with MS-associated fatigue were enrolled for 10 weeks: 2-week baseline, 4-week intervention, 4-week washout.
Results
41 participants were enrolled; 35 were randomized (average age 42 years, 80% female; BWLT
n
= 20; DRLT
n
= 15). 31 were in the intention to treat analysis. The average duration of LT sessions was similar between groups (BWLT 60.9 min, DRLT 61.5 min,
p
= 0.70). The most commonly reported adverse event was headache. There were no events that led to discontinuation. Baseline fatigue was severe in both arms (each 53/63 points on the Fatigue Severity Scale (FSS),
p
= 0.92). FSS was lower following BWLT (FSS 45.8 post-LT,
p
= 0.04; 44.9 post-washout,
p
= 0.02 intra-group compared to baseline FSS) and DRLT (FSS 46.7 post-LT,
p
= 0.03; 43.9 post-washout,
p
= 0.002 intragroup compared to baseline FSS). There was no difference between BWLT and DRLT groups in the magnitude of reduction of FSS scores (
p
= 0.81 after LT;
p
= 0.77 after washout for between group comparisons). Similarly, MS quality of life metrics improved in both arms but were not significantly different between groups after LT (
p
= 0.22) or washout.
Conclusions
LT is safe, feasible, and well-tolerated in people with MS-associated fatigue. Improvement in both light spectra likely indicates a strong placebo effect for the DRLT group.</description><subject>Fatigue</subject><subject>Headache</subject><subject>Light therapy</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Multiple sclerosis</subject><subject>Neurology</subject><subject>Neuroradiology</subject><subject>Neurosciences</subject><subject>Original Communication</subject><subject>Placebos</subject><subject>Quality of life</subject><issn>0340-5354</issn><issn>1432-1459</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNp9kD1vFDEQhi1ERI7AH6BAlmgocBh_7O2aLor4OOkkGqiNzzt758i7XmyvovDr4-MCSBQpRlPMM--MHkJecbjkAO37DKB4w0AAA92pht0-ISuupGBcNfopWYFUwBrZqHPyPOcbAKiUfkbOpZBS8nW3Ij-2fn8otBww2fmODjHRcQnFzwFpdgFTzD4zm3N03hbs6WCL3y_4gVqa7NTH0f_C_h11cSophlCJ-WAz0s2GluRteEHOBhsyvnzoF-T7p4_frr-w7dfPm-urLXOK68LEGm1r12LnXOOUA27bHgV2uJZCtbWGnbay0bprGw44CAVCV1LtoNPaCXlB3p5y5xR_LpiLGX12GIKdMC7ZCKlV1-pWthV98x96E5c01e-MUEcznVZHSpwoVx3khIOZkx9tujMczNG_Ofk31b_57d_c1qXXD9HLbsT-78of4RWQJyDX0bTH9O_2I7H32MaQdQ</recordid><startdate>20200801</startdate><enddate>20200801</enddate><creator>Mateen, Farrah J.</creator><creator>Vogel, Andre C.</creator><creator>Kaplan, Tamara B.</creator><creator>Hotan, Gladia C.</creator><creator>Grundy, Sara J.</creator><creator>Holroyd, Kathryn B.</creator><creator>Manalo, Natalie</creator><creator>Stauder, Matthew</creator><creator>Videnovic, Aleksandar</creator><general>Springer Berlin Heidelberg</general><general>Springer Nature B.V</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7TK</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope></search><sort><creationdate>20200801</creationdate><title>Light therapy for multiple sclerosis-associated fatigue: a randomized, controlled phase II trial</title><author>Mateen, Farrah J. ; Vogel, Andre C. ; Kaplan, Tamara B. ; Hotan, Gladia C. ; Grundy, Sara J. ; Holroyd, Kathryn B. ; Manalo, Natalie ; Stauder, Matthew ; Videnovic, Aleksandar</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c419t-26ea7a62bcc5c4c01a7de2e8e63247324fb9a359987510ef240295c44b0899c23</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Fatigue</topic><topic>Headache</topic><topic>Light therapy</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Multiple sclerosis</topic><topic>Neurology</topic><topic>Neuroradiology</topic><topic>Neurosciences</topic><topic>Original Communication</topic><topic>Placebos</topic><topic>Quality of life</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Mateen, Farrah J.</creatorcontrib><creatorcontrib>Vogel, Andre C.</creatorcontrib><creatorcontrib>Kaplan, Tamara B.</creatorcontrib><creatorcontrib>Hotan, Gladia C.</creatorcontrib><creatorcontrib>Grundy, Sara J.</creatorcontrib><creatorcontrib>Holroyd, Kathryn B.</creatorcontrib><creatorcontrib>Manalo, Natalie</creatorcontrib><creatorcontrib>Stauder, Matthew</creatorcontrib><creatorcontrib>Videnovic, Aleksandar</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Neurosciences Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of neurology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Mateen, Farrah J.</au><au>Vogel, Andre C.</au><au>Kaplan, Tamara B.</au><au>Hotan, Gladia C.</au><au>Grundy, Sara J.</au><au>Holroyd, Kathryn B.</au><au>Manalo, Natalie</au><au>Stauder, Matthew</au><au>Videnovic, Aleksandar</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Light therapy for multiple sclerosis-associated fatigue: a randomized, controlled phase II trial</atitle><jtitle>Journal of neurology</jtitle><stitle>J Neurol</stitle><addtitle>J Neurol</addtitle><date>2020-08-01</date><risdate>2020</risdate><volume>267</volume><issue>8</issue><spage>2319</spage><epage>2327</epage><pages>2319-2327</pages><issn>0340-5354</issn><eissn>1432-1459</eissn><abstract>Background
Bright white light therapy (LT) can improve fatigue in several disease states but has not been studied in multiple sclerosis (MS).
Objective
To determine whether controlled home-based LT is feasible, tolerable, and well-adhered to in MS-associated fatigue.
Methods
A randomized, controlled trial of twice-daily 1-h bright white LT (BWLT) (10,000 lx, active arm) versus dim red LT (DRLT) (< 300 lx, control arm) was performed. Adults with MS-associated fatigue were enrolled for 10 weeks: 2-week baseline, 4-week intervention, 4-week washout.
Results
41 participants were enrolled; 35 were randomized (average age 42 years, 80% female; BWLT
n
= 20; DRLT
n
= 15). 31 were in the intention to treat analysis. The average duration of LT sessions was similar between groups (BWLT 60.9 min, DRLT 61.5 min,
p
= 0.70). The most commonly reported adverse event was headache. There were no events that led to discontinuation. Baseline fatigue was severe in both arms (each 53/63 points on the Fatigue Severity Scale (FSS),
p
= 0.92). FSS was lower following BWLT (FSS 45.8 post-LT,
p
= 0.04; 44.9 post-washout,
p
= 0.02 intra-group compared to baseline FSS) and DRLT (FSS 46.7 post-LT,
p
= 0.03; 43.9 post-washout,
p
= 0.002 intragroup compared to baseline FSS). There was no difference between BWLT and DRLT groups in the magnitude of reduction of FSS scores (
p
= 0.81 after LT;
p
= 0.77 after washout for between group comparisons). Similarly, MS quality of life metrics improved in both arms but were not significantly different between groups after LT (
p
= 0.22) or washout.
Conclusions
LT is safe, feasible, and well-tolerated in people with MS-associated fatigue. Improvement in both light spectra likely indicates a strong placebo effect for the DRLT group.</abstract><cop>Berlin/Heidelberg</cop><pub>Springer Berlin Heidelberg</pub><pmid>32333168</pmid><doi>10.1007/s00415-020-09845-w</doi><tpages>9</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0340-5354 |
| ispartof | Journal of neurology, 2020-08, Vol.267 (8), p.2319-2327 |
| issn | 0340-5354 1432-1459 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2394879737 |
| source | SpringerLink Journals - AutoHoldings |
| subjects | Fatigue Headache Light therapy Medicine Medicine & Public Health Multiple sclerosis Neurology Neuroradiology Neurosciences Original Communication Placebos Quality of life |
| title | Light therapy for multiple sclerosis-associated fatigue: a randomized, controlled phase II trial |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-11T21%3A37%3A00IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Light%20therapy%20for%20multiple%20sclerosis-associated%20fatigue:%20a%20randomized,%20controlled%20phase%20II%20trial&rft.jtitle=Journal%20of%20neurology&rft.au=Mateen,%20Farrah%20J.&rft.date=2020-08-01&rft.volume=267&rft.issue=8&rft.spage=2319&rft.epage=2327&rft.pages=2319-2327&rft.issn=0340-5354&rft.eissn=1432-1459&rft_id=info:doi/10.1007/s00415-020-09845-w&rft_dat=%3Cproquest_cross%3E2423338947%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2423338947&rft_id=info:pmid/32333168&rfr_iscdi=true |